10 Best Biotech Stocks Under $10 to Buy

8. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 27

Market Capitalization as of October 27: $9.15 Billion

Share Price as of October 27: $8.63

ImmunityBio, Inc. has staged a remarkable rally in 2026, gaining over 300% and dwarfing the biotechnology sector’s 31% gain in the S&P 500. The rally reflects growing investor optimism about the commercial potential of ANKTIVA, a lead cancer immunotherapy product.

A $5.8 Billion Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX) explores the growing market opportunity behind the company’s prospects and the factors driving investor interest in its cancer treatment portfolio.

The market is pricing ImmunityBio at a premium on the rapid expansion of sales of its lead product. Net product revenue increased 121% in the first half of the year to $94.8 million. The U.S. Food and Drug Administration has already approved it for an additional group of patients with high-grade papillary-only, non-muscle-invasive bladder cancer.

ImmunityBio, Inc. has also expanded Anktiva’s reach beyond the US and into the United Arab Emirates, in addition to five other regulatory jurisdictions. The push should create additional revenue opportunities as the company pursues broader market access.

Wall Street is already taking note of ImmunityBio’s pipeline development milestone. On October 14, Jefferies reiterated a Buy rating on the stock and raised the price target to $14 from $12, buoyed by expanded coverage of the lead product, ANKTIVA. Piper Sandler also raised its price target to $16 from $12 following the FDA approval.

These upward revisions reflect optimism about ANKTIVA’s broader commercial opportunity. However, the substantial difference between ImmunityBio’s current valuation and the biotechnology sector average suggests that investors are already pricing in considerable future growth.

7. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 30

Market Capitalization as of October 27: $2.41 Billion

Share Price as of October 27: $4.05

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best biotech stocks under $10 to buy, supported by its AI-powered drug discovery platform. Although the stock has remained relatively flat in 2026, it has gained more than 20% over the past six months, signaling renewed investor interest in the company’s long-term growth prospects.

On October 16, a Morgan Stanley analyst reiterated an Equal Weight rating on the stock but raised the price target to $5.90 from $5.30. The bullish thesis follows Genentech’s advancement of its first neuroscience target and its early-discovery program.

Additionally, the stock’s sentiment improved after positive results on the development of REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis (FAP). It is also advancing REC-1245, an investigational RBM39 drug for advanced solid tumors.

These programs highlight the potential of its technology platform to identify and advance drug candidates across multiple therapeutic areas. Gain insights into the company’s pipeline development.

Recursion Pharmaceuticals Inc. also received a boost on October 15 as Sanofi optioned the first development candidate under their strategic partnership. The agreement positions the company to receive a $10 million milestone payment, providing additional financial support as it advances its drug discovery programs. Explore how Recursion has entered a new growth phase on the Sanofi deal.

6. Maravai LifeSciences (NASDAQ:MRVI)

Number of Hedge Fund Holders: 33

Market Capitalization as of October 27: $2.14 Billion

Share Price as of October 27: $8.26

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has rallied more than 100% as investors increasingly recognize the potential of its specialized nucleic acid production technologies and biologics safety-testing products. Improving performance in mRNA-related business has strengthened the investment case as one of the best biotech stocks under $10 to buy.

TriLink Biotechnologies is the company’s main growth engine, supplying materials for mRNA research and clinical development. The unit’s revenue rose 11.5% in the second quarter to $34.7 million, driven by strong demand for both Discovery and GMP consumables.

Additionally, TriLink revenue rose 37.3% in the first half of the year, driven by high-volume CleanCap orders for commercial-phase COVID vaccine programs. Newer technologies gaining wider adoption could help the company increase revenue per customer and strengthen its position in the mRNA supply chain.

Wall Street analysts are also becoming more constructive on the company’s prospects. On October 5, TD Cowen initiated coverage of the stock with a Buy rating and a $9 price target, highlighting the substantial opportunity in non-COVID mRNA applications alongside continued growth in CleanCap revenue. Read how Maravai has made a comeback.

Maravai LifeSciences Holdings, Inc.’s proprietary nucleic acid technologies, growing ModTail customer base, GMP manufacturing capabilities, and improving operating performance provide a potential path toward stronger earnings.

5. Savara Inc. (NASDAQ:SVRA)

Number of Hedge Fund Holders: 36

Market Capitalization as of October 27: $1.03 Billion

Share Price as of October 27: $4.86

Savara Inc. (NASDAQ:SVRA) is an emerging high-risk, high-reward investment opportunity as it advances its lead drug candidate, molgramostim inhalation solution, MOLBREEVI. The inhaled treatment is designed to address autoimmune pulmonary alveolar proteinosis (aPAP), a rare and potentially serious lung disease.

The US Food and Drug Administration (FDA) has accepted Savara’s biologics license application (BLA) for MOLBREEVI, bringing the company closer to a potential regulatory decision. Approval would pave the way for commercialization and mark a significant milestone in Savara’s transition from a clinical-stage biotechnology company to a commercial-stage rare disease business. What Does Wall Street Think About Savara?

Wall Street has also expressed confidence in theSavara Inc.’s prospects. On October 7, JPMorgan initiated coverage of the stock with an Overweight rating and a $12 price target, citing the potential for MOLBREEVI approval in the United States, the United Kingdom, and the European Union to unlock substantial commercial opportunities. Savara ended the second quarter with $173 million in cash and cash equivalents, providing financial resources to support launch preparations and advance its commercialization strategy.

Photo from Iovance Biotherapeutics website

Read Also: Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections

Savara Inc.’s edge as one of the best biotech stocks under 10 to buy hinges on MOLBREEVI becoming the first approved pharmacological treatment for autoimmune PAP. Regulatory approval would open the door to a commercial business built around an underserved rare respiratory disease. Positive clinical findings, regulatory applications in multiple markets, and cash reserves to support launch preparations provide the foundation for that opportunity.